Reply to “Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach”

Peer Review reports

Original Submission
6 Feb 2024	Submitted	Original manuscript
29 Feb 2024	Reviewed	Reviewer Report - Matthew Walton
8 Mar 2024	Reviewed	Reviewer Report
21 Mar 2024	Author responded	Author comments - Yuanyi Cai
Resubmission - Version 2
21 Mar 2024	Submitted	Manuscript version 2
22 Mar 2024	Reviewed	Reviewer Report - Matthew Walton
22 Mar 2024	Reviewed	Reviewer Report
28 Mar 2024	Author responded	Author comments - Yuanyi Cai
Resubmission - Version 3
28 Mar 2024	Submitted	Manuscript version 3
5 Apr 2024	Reviewed	Reviewer Report
5 Apr 2024	Reviewed	Reviewer Report - Matthew Walton
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
19 Apr 2024	Editorially accepted
22 Jul 2024	Article published	10.1186/s12885-024-12288-5

Back to article page